Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01606982 | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 0 |
| Feb 17, 2017 |
| clinicaltrials |
| NCT02421575 | Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance | terminated | Early Phase 1 | 4 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 2, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT01347788 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT02964351 | microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer | unknown | — | 120 | Assuta Medical CenterOTHER | 0 | Nov 16, 2016 | clinicaltrials |
| NCT02002455 | Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI(Flucipro) | completed | Phase 2 | 26 | Turku University HospitalOTHER_GOV | 1 | Oct 21, 2016 | clinicaltrials |
| NCT02935023 | Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 47 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT02128334 | An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation | completed | — | 645 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Aug 16, 2016 | clinicaltrials |
| NCT01325311 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02424448 | Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer(BIOMETHS) | completed | — | 6 | The Christie NHS Foundation TrustOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02140138 | An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer | terminated | Phase 2 | 35 | CureVacINDUSTRY | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00321646 | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 42 | Mary-Ellen Taplin, MDOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT02484339 | Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)(α-RT) | unknown | Phase 2 | 274 | University Hospital FreiburgOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01219790 | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma(GEMO) | completed | Phase 1 | 30 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01812746 | A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | BIND TherapeuticsINDUSTRY | 1 | Apr 15, 2016 | clinicaltrials |
| NCT00438464 | Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery | completed | Phase 2 | 204 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT02130947 | Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00450229 | Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT02396368 | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer(Radium-223) | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT02024685 | Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial | terminated | N/A | 76 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2015 | clinicaltrials |
| NCT01898065 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer(HYPOXProstat) | completed | Phase 2 | 20 | Institut Cancerologie de l'OuestOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01541007 | A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer(ConCab) | completed | Phase 2 | 100 | Jeffrey Yachnin M.D., PhD.OTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT01621425 | Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity(LEANDOC) | completed | — | 25 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01011751 | Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma | completed | Phase 3 | 311 | TakedaINDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | withdrawn | Phase 2 | 0 | Nicholas MitsiadesOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT02502994 | Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC | unknown | Phase 1 | 12 | Norio NonomuraOTHER | 1 | Jul 20, 2015 | clinicaltrials |
| NCT00936975 | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2015 | clinicaltrials |
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01533246 | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00080899 | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00666666 | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01838265 | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management(MGM) | withdrawn | — | 0 | University of MiamiOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT01497431 | Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT01610050 | A Phase I Study of LFA102 in Japanese Patients | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 11, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00459407 | Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2014 | clinicaltrials |
| NCT02258087 | HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.(PROMOBRA) | unknown | Phase 2 / Phase 3 | 50 | National Institute of Oncology, HungaryOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT02237612 | Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer | completed | N/A | 9 | University of Southern CaliforniaOTHER | 1 | Sep 11, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00087139 | Ixabepilone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00110214 | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 3 | 1,050 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2017source: clinicaltrials